|
|
|
| Webinar: The mRNA Journey: From Design to LNP-Ready Molecules for Research | Discover an optimized end-to-end workflow for producing high-quality IVT mRNA for research applications. This Agilent webinar covers every step—from sequence design and PCR-based DNA template preparation to transcription, lipid nanoparticle formulation, and QC testing with Agilent TapeStation and Fragment Analyzer systems—enabling fast, reliable, small-scale mRNA production for non-clinical research such as vaccines, protein expression, and gene or cell therapy. Watch it here. |
|
|
|
|
By Anna Rose Welch, Editorial & Community Director, Advancing RNA | Now, I cannot claim that I or any of the panelists at CASSS have or had access to a real crystal ball that will show us the future. However, what did come through these discussions loud and clear is that the future of our industry must include “balance.” Here, I’ll unpack a few ways the theme of “balance” presented itself — and no doubt will continue to present itself in the future — as well as how the panelists see us achieving this necessary balance. | |
|
|
Emerging RNA Delivery Strategies For Solid Tumor Oncology | By Jyotsna Jajula, Wayne State University | RNA shows promise in solid tumors, but delivery remains the core challenge. New targeting and delivery strategies aim to overcome tumor barriers and unlock RNA’s full therapeutic potential. |
|
|
The Purification Dilemma: Balancing Upstream & Downstream Investment | By Advancing RNA Live | This Advancing RNA Live clip dives into the biggest challenges in mRNA purification and the critical debate on where to focus investment. Here, our three mRNA PD experts argue for a holistic process development strategy, challenging the traditional wisdom of optimizing the upstream process at any cost. |
|
|
The 9 Fastest-Growing Outsourcing Segments | By Jeffrey S. Buguliskis, Ph.D., Deputy Chief Editor, Outsourced Pharma | Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early. |
|
|
|
|
|
|
| The Absolute Essentials Of Manufacturability | Article | By Maik W. Jornitz, BioProcess Resources LLC, DIANT Pharma | Read why integrating Quality by Design (QbD) and Process Analytical Technology (PAT) early on is essential for developing a robust, controlled, and financially viable process. |
|
|
|
|
|
|
| Empowering A New Era Of Patient-Centric Medicines | Podcast | Nanoform | Discover the challenges pharma companies are facing as they switch focus as well as the actions and technologies companies are implementing to help achieve a brighter future for patients. |
|
|
|
| Expand Your Toolbox For Quality mRNA Manufacturing | White Paper | Roche CustomBiotech | Review these guidelines for the use of SP6 RNA Polymerase in mRNA synthesis to determine if is a good alternative for your specific template and optimize your process. |
|
|
| Building Local Biomanufacturing Capacity In South Africa | White Paper | By Jennifer Brant and David Marion, Uptown Communications Consultants, MilliporeSigma | Biovac evolved from a vaccine supplier to a biopharmaceutical innovator, providing a blueprint for expanding Africa's vaccine manufacturing capacity. Gain valuable insights from their journey. |
|
|
|
|
| Translating Novel siRNA & microRNA Drugs from Bench To Bedside | Returning as the industry's premier dedicated forum, the 7th RNAi-Based Therapeutics Summit is the only event uniting the entire RNA interference ecosystem to translate the next wave of siRNA and microRNA drugs from bench to bedside. It will go beyond the liver, focusing on the novel strategies turning extra-hepatic delivery into a clinical reality. Find Out More. |
|
|
|
|
|
|
|
|
.png){kind=logo}
